[go: up one dir, main page]

MX2009002590A - Partículas de núcleo dividido para la presentación de moléculas extrañas, especialmente para aplicaciones en vacunas, y método para producirlas. - Google Patents

Partículas de núcleo dividido para la presentación de moléculas extrañas, especialmente para aplicaciones en vacunas, y método para producirlas.

Info

Publication number
MX2009002590A
MX2009002590A MX2009002590A MX2009002590A MX2009002590A MX 2009002590 A MX2009002590 A MX 2009002590A MX 2009002590 A MX2009002590 A MX 2009002590A MX 2009002590 A MX2009002590 A MX 2009002590A MX 2009002590 A MX2009002590 A MX 2009002590A
Authority
MX
Mexico
Prior art keywords
core
split
particles
domain
presentation
Prior art date
Application number
MX2009002590A
Other languages
English (en)
Inventor
Michael Nassal
Claudia Skamel
Andreas Walker
Original Assignee
Universitaetsklinikum Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Freiburg filed Critical Universitaetsklinikum Freiburg
Publication of MX2009002590A publication Critical patent/MX2009002590A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen sustancias portadoras del núcleo dividido ("Split-core") que, como polipéptidos separados. Tiene el dominio nuclear N y el dominio nuclear C de la proteína nuclear de un virus de la hepatitis B, y al menos una molécula extraña contra la cual ha de provocarse una respuesta inmune. De acuerdo con la invención, la molécula extraña, especialmente la secuencia de aminoácidos extraña heteróloga, ésta fusionada al extremo C del dominio nuclear N o el extremo N del dominio nuclear C, y la proteína nuclear puede formar partículas similares a cápsides. La invención también se relaciona con un método de producción asociado.
MX2009002590A 2006-09-08 2007-07-12 Partículas de núcleo dividido para la presentación de moléculas extrañas, especialmente para aplicaciones en vacunas, y método para producirlas. MX2009002590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06018847A EP1897887A1 (de) 2006-09-08 2006-09-08 Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung
PCT/EP2007/006190 WO2008028535A1 (de) 2006-09-08 2007-07-12 Split-core-partikel für die präsentation von fremdmolekülen, insbesondere für impfstoffartwendungen und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
MX2009002590A true MX2009002590A (es) 2009-08-24

Family

ID=37672012

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002590A MX2009002590A (es) 2006-09-08 2007-07-12 Partículas de núcleo dividido para la presentación de moléculas extrañas, especialmente para aplicaciones en vacunas, y método para producirlas.

Country Status (22)

Country Link
US (1) US8282932B2 (es)
EP (2) EP1897887A1 (es)
JP (1) JP5160545B2 (es)
KR (1) KR20090059118A (es)
CN (1) CN101541828B (es)
AT (1) ATE538134T1 (es)
AU (1) AU2007294249B2 (es)
BR (1) BRPI0716545A2 (es)
CA (1) CA2662707C (es)
CO (1) CO6160336A2 (es)
CY (1) CY1112309T1 (es)
DK (1) DK2059525T3 (es)
ES (1) ES2377742T3 (es)
MX (1) MX2009002590A (es)
MY (1) MY146926A (es)
NZ (1) NZ575360A (es)
PL (1) PL2059525T3 (es)
PT (1) PT2059525E (es)
RU (1) RU2454462C2 (es)
SI (1) SI2059525T1 (es)
WO (1) WO2008028535A1 (es)
ZA (1) ZA200901825B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2528940T1 (sl) * 2010-01-25 2014-07-31 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
CN102464721B (zh) * 2010-11-17 2015-05-20 中国科学院上海巴斯德研究所 针对人肠道病毒71型的重组广谱性疫苗
WO2015133613A1 (ja) * 2014-03-07 2015-09-11 雅史 溝上 Ｂ型肝炎ウイルスレポーターベクター、ｂ型肝炎ウイルス様粒子及びそれを用いたｂ型肝炎治療薬のスクリーニング方法
ES2898273T3 (es) 2014-03-20 2022-03-04 Bristol Myers Squibb Co Moléculas con una estructura a base de fibronectina estabilizada
WO2019028266A1 (en) * 2017-08-02 2019-02-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services HEPATITIS B NANOPARTICLE VACCINE FOR INFLUENZA VIRUS
CN108048480B (zh) * 2017-11-24 2021-04-23 湖北大学 一种split-TEV-Fast系统的构建方法及其在检测蛋白相互作用中的应用
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
US20230405111A1 (en) * 2020-07-24 2023-12-21 West China Hospital Of Sichuan University Ebv-targeted allogeneic b cell vaccine and preparation method therefor
EP4373839A4 (en) * 2021-07-20 2025-12-17 Univ Johns Hopkins SUPRAMOLECULAR POLYMERS WITH HIGH AFFINITY FOR BINDING-RESULTED ANTIBODY PRECIPITATION AND CLEANSING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine

Also Published As

Publication number Publication date
DK2059525T3 (da) 2012-03-05
JP2010502658A (ja) 2010-01-28
SI2059525T1 (sl) 2012-03-30
WO2008028535A1 (de) 2008-03-13
CN101541828A (zh) 2009-09-23
CO6160336A2 (es) 2010-05-20
PT2059525E (pt) 2012-02-27
EP2059525A1 (de) 2009-05-20
RU2454462C2 (ru) 2012-06-27
BRPI0716545A2 (pt) 2013-04-02
CA2662707C (en) 2016-06-21
EP2059525B1 (de) 2011-12-21
ES2377742T3 (es) 2012-03-30
CN101541828B (zh) 2013-09-04
CA2662707A1 (en) 2008-03-13
US8282932B2 (en) 2012-10-09
PL2059525T3 (pl) 2012-04-30
US20100040646A1 (en) 2010-02-18
ZA200901825B (en) 2010-03-31
AU2007294249B2 (en) 2011-10-20
AU2007294249A1 (en) 2008-03-13
CY1112309T1 (el) 2015-12-09
KR20090059118A (ko) 2009-06-10
MY146926A (en) 2012-10-15
EP1897887A1 (de) 2008-03-12
NZ575360A (en) 2010-11-26
ATE538134T1 (de) 2012-01-15
RU2009112721A (ru) 2010-10-20
JP5160545B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
MX2009002590A (es) Partículas de núcleo dividido para la presentación de moléculas extrañas, especialmente para aplicaciones en vacunas, y método para producirlas.
EP3670536A3 (en) Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2009007244A3 (en) Replication deficient influenza virus for the expression of heterologous sequences
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
WO2008148104A8 (en) Novel vlps derived from cells that do not express a viral matrix or core protein
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
IN2013MN02441A (es)
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
WO2010117760A3 (en) Fusion proteins comprising canine fc portions
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2018093932A3 (en) Nucleic acids for treatment of allergies
WO2007118206A3 (en) Canine influenza virus
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
GB2496801A (en) A method of treating alzheimer's disease
MX363443B (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
MX366493B (es) Composiciones y su uso en el tratamiento de cánceres cerebrales.
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
NZ724196A (en) Uti fusion proteins
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
RU2010125678A (ru) Способ получения рекомбинантной вакцины

Legal Events

Date Code Title Description
FG Grant or registration